The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Risk-adapted therapy guided by human papillomavirus (HPV) circulating tumor DNA in patients with HPV-positive oropharyngeal cancer (ReACT 1.0).
 
Glenn Hanna
Employment - Dana-Farber Cancer Institute
Honoraria - Massachusetts Medical Society
Consulting or Advisory Role - Bicara Therapeutics; Boxer Capital; Bristol-Myers Squibb; Coherus Biosciences; Coherus Biosciences; Elevar Therapeutics; Grey Wolf Therapeutics; InhibRx; KSQ Therapeutics; Kura Oncology; Merck; Naveris; Nextech Invest; PDS Biotechnology; Remix Therapeutics; Replimune; Surface Oncology
Research Funding - Actuate Therapeutics (Inst); Adenoid Cystic Carcinoma Research Foundation (Inst); ASCO (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Gateway for Cancer Research; Genentech (Inst); ImmunityBio (Inst); Kura Oncology (Inst); Regeneron (Inst); Secura Bio (Inst)
 
Tulika Gupta
No Relationships to Disclose
 
Lorenzo Trippa
No Relationships to Disclose
 
Emily Kim
No Relationships to Disclose
 
Alexander Droznin
No Relationships to Disclose
 
Jacqueline Minken
No Relationships to Disclose
 
Lauren Gunasti
No Relationships to Disclose
 
Eleni Rettig
Research Funding - Naveris
Other Relationship - Naveris
 
Danielle Margalit
No Relationships to Disclose
 
Roy Tishler
No Relationships to Disclose
 
Itai Pashtan
No Relationships to Disclose
 
Kartik Sehgal
Honoraria - Academy for Continued Healthcare Learning; AmerisourceBergen; Binacea; Medscape; Pri-Med
Consulting or Advisory Role - Equinox Group; Exelixis; Guidepoint Global; Medscape; Pfizer; Scholar Rock
Research Funding - Merck (Inst)
Travel, Accommodations, Expenses - Binacea; Merck; Pfizer; Pri-Med
 
Michael Dennis
Employment - Dana Farber Cancer Hospital
Honoraria - Coherus Biosciences
Consulting or Advisory Role - MJH Life Sciences
Speakers' Bureau - Dr. Reddy's Laboratories
Travel, Accommodations, Expenses - Dr. Reddy's Laboratories
 
Rosh Sethi
No Relationships to Disclose
 
Donald Annino
No Relationships to Disclose
 
Laura Goguen
No Relationships to Disclose
 
Jeffrey Guenette
No Relationships to Disclose
 
Ravindra Uppaluri
Consulting or Advisory Role - Daichi-Sankyo; Merck; Regeneron
Research Funding - Daichi-Sankyo; Merck
Patents, Royalties, Other Intellectual Property - Washington University licenses mouse oral cancer cell lines made by my lab. I receive royalties from Washington University from these agreements.
 
Robert Haddad
Employment - Dana-Farber Cancer Institute
Leadership - NCCN
Stock and Other Ownership Interests - tosk
Consulting or Advisory Role - ALX Oncology; AstraZeneca; aveo; Bayer; Boehringer Ingelheim; Eisai; EMD Serono; Genmab; Genzyme; GlaxoSmithKline; Johnson & Johnson/Janssen; Merck; PDS Biotechnology; Scholar Rock
Research Funding - AstraZeneca (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Kura Oncology (Inst); Merck (Inst); Merus (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
Other Relationship - Boehringer Ingelheim; Hookipa Pharma; ISA Pharmaceuticals; Nanobiotix
 
Jonathan Schoenfeld
Employment - Brigham and Women's Hospital
Stock and Other Ownership Interests - Immunitas; Intragel
Consulting or Advisory Role - EMD Serono; Immunitas; Merck KGaA
Research Funding - Bristol-Myers Squibb; EMD Serono/Merck; Merck; Regeneron; Siemens
Patents, Royalties, Other Intellectual Property - MAGEA1 IMMUNOGENIC PEPTIDES, BINDING PROTEINS RECOGNIZING MAGEA1 IMMUNOGENIC PEPTIDES, AND USES THEREOF; Nanobody bioconjugation for immune receptor targeting
Expert Testimony - Burns and White